AVROBIO Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

AVROBIO General Information

Description

Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Contact Information

Website
www.avrobio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Corporate Office
  • One Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AVROBIO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 20-Jun-2024 00000 Completed Generating Revenue
9. Merger/Acquisition 08-Feb-2023 Cancelled Generating Revenue
8. Secondary Transaction - Open Market 00000 Completed Generating Revenue
7. Secondary Transaction - Open Market 00000 Completed Generating Revenue
6. Secondary Transaction - Open Market 28-Sep-2018 00000 Completed Clinical Trials - Phase 2
5. IPO 21-Jun-2018 00000 00000 00000 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 02-Feb-2018 000.00 0000 00000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 30-Mar-2017 0000 000.00 000.00 Completed Clinical Trials - Phase 2
2. Accelerator/Incubator 01-Jun-2016 $1.5M Completed Startup
1. Seed Round 18-Feb-2016 $1.5M $1.5M 000 Completed Startup
To view AVROBIO’s complete valuation and funding history, request access »

AVROBIO Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 3,333,333 $0.000100 $0.02 $0.45 $0.45 1x $0.45 4.19%
To view AVROBIO’s complete cap table history, request access »

AVROBIO Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo
Biotechnology
Cambridge, MA
13 As of 2023
00000
000000&0 00000

000000

ute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000000000000
Cambridge, MA
000 As of 0000
00000
00000000 00000

000000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000000000000
Houston, TX
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AVROBIO Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
Alaunos Therapeutics Formerly VC-backed Houston, TX 00 00000 00000000000 00000
Ember Therapeutics Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
Chemocentryx Formerly VC-backed Mountain View, CA 000 00000 000000&0 00000
TScan Therapeutics Formerly VC-backed Waltham, MA 000 00000 00000000 00000
You’re viewing 5 of 62 competitors. Get the full list »

AVROBIO Executive Team (18)

Name Title Board Seat
Erik Ostrowski Interim Chief Executive Officer & Chief Financial Officer, Finance
Azadeh Golipour Chief Technology Officer
Christopher Mason MD Chief Scientific Officer & Founder
Deanna Petersen Chief Business Officer
Diana Escolar Ph.D Chief Medical Officer
You’re viewing 5 of 18 executive team members. Get the full list »

AVROBIO Board Members (10)

Name Representing Role Since
Annalisa Jenkins MD Self Board Member 000 0000
Bruce Booth Ph.D Atlas Venture Chairman & Board Member 000 0000
Christopher Paige Ph.D AVROBIO Co-Founder & Board Member 000 0000
You’re viewing 3 of 10 board members. Get the full list »

AVROBIO Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AVROBIO Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
5Y Capital Venture Capital Minority 000 0000 000000 0
Aisling Capital Venture Capital Minority 000 0000 000000 0
Atlas Venture Venture Capital Minority 000 0000 000000 0
Brace Pharma Capital Corporate Venture Capital Minority 000 0000 000000 0
Citadel Enterprise Americas Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

AVROBIO Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tectonic Therapeutic 30-Jan-2024 0000000 00 Drug Discovery
To view AVROBIO’s complete acquisitions history, request access »

AVROBIO FAQs

  • When was AVROBIO founded?

    AVROBIO was founded in 2015.

  • Who is the founder of AVROBIO?

    Christopher Mason MD, Christopher Mason MD, Jeffrey Medin Ph.D, and Geoff MacKay are the founders of AVROBIO.

  • Who is the CEO of AVROBIO?

    Erik Ostrowski is the CEO of AVROBIO.

  • Where is AVROBIO headquartered?

    AVROBIO is headquartered in Cambridge, MA.

  • What is the size of AVROBIO?

    AVROBIO has 13 total employees.

  • What industry is AVROBIO in?

    AVROBIO’s primary industry is Biotechnology.

  • Is AVROBIO a private or public company?

    AVROBIO is a Private company.

  • What is AVROBIO’s current revenue?

    The current revenue for AVROBIO is 00000.

  • How much funding has AVROBIO raised over time?

    AVROBIO has raised $187M.

  • Who are AVROBIO’s investors?

    5Y Capital, Aisling Capital, Atlas Venture, Brace Pharma Capital, and Citadel Enterprise Americas are 5 of 9 investors who have invested in AVROBIO.

  • Who are AVROBIO’s competitors?

    Voyager Therapeutics, Alaunos Therapeutics, Ember Therapeutics, Chemocentryx, and TScan Therapeutics are some of the 62 competitors of AVROBIO.

  • When was AVROBIO acquired?

    AVROBIO was acquired on 20-Jun-2024.

  • Who acquired AVROBIO?

    AVROBIO was acquired by Tectonic Therapeutic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »